Experimental device trial launches – safety first

NCT ID NCT06609265

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Aug 14, 2026 · Updated 6 times

Summary

This trial is testing a device that has not been approved by the U.S. FDA. The purpose is to learn about its safety and how it works in the body. Participants will help researchers understand if the device is promising for future use.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 140 people

The number the study aims to enrol. It can still change while the study runs.

Started

May 2025

Expected to finish

Nov 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 50 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Male or female 18 - 50 years of age who engage in greater than or equal to 2.5 hours a week of physical activity (in any sport, with the primary aim to maintain health and fitness), at screening. * Documentation of pelvic or lower extremity BSI diagnosis as evidenced by one or more clinical features consistent with the high-grade BSI by MRI grading (stress reactions of MRI grade 3 or stress fracture, grade 4 by Fredericson MRI Grading) with specific stress injury sites to be included: pelvis (including pubic ramus and sacrum), compression-sided femoral neck with fracture line less than 50% diameter if grade 4, femoral shaft, posteromedial tibia, calcaneus, metatarsal (2nd-4th, excluding proximal 2nd), and fibula. * Written informed consent obtained from subject or subject's legal representative and ability for subject to comply with the requirements of the study. * If on NSAIDs, willing to refrain from use during the study. * If female of child-bearing potential, both of the following must be met at screening: * Practices one of the following methods of contraception and continues through the duration of the study: abstinence, hormonal contraceptives, IUD, spermicide and barrier or implantable device, and * Has a negative urine qualitative beta-HCG pregnancy test. * If female and post-menopausal one of the following must be met at screening: * Has had a complete hysterectomy, bilateral salpingo-oophorectomy or tubal ligation or otherwise be incapable of pregnancy, or * Is postmenopausal for at least one year. Exclusion Criteria: * Pregnant, breastfeeding, plans to become pregnant during the study, or unwilling to practice birth control during participation in the study. * Unsuitable candidate for the study, based on the opinion of the investigator (e.g. cognitive impairment), such that participation might create undue risk to the subject or interfere with the subject\'s ability to comply with the protocol requirements or complete the study. * Subjects who, at entry, are known to have alternative treatment (e.g. surgery) planned within the next 8 weeks. * History of severe osteoporosis (prior DXA scan with Z-score of -3.0 or T-score less than or equal to -2.5 and prior fracture history) or other underlying bone disease/disorder. * Chronic rheumatologic condition and/or history of chronic oral steroid use. * Type II diabetes, other chronic underlying disease. * Morbid obesity (Body Mass Index greater than or equal to 35) at screening. * Has clinically significant renal disease defined as having an estimated creatinine clearance of greater than or equal to 40mL/min at screening. * History of osteomyelitis in the injured area on which the treatment is to be administered at screening. * Has a current history of substance abuse (current is defined as within 120 days of screening). * Has evidence of a prior fracture or BSI within the last 6 months in the same area as the current injury. * Has active cellulitis or wound either at the injury site, or in the surrounding area at screening. * Has an injury requiring surgical intervention at screening. * Current/active DSM-V eating disorder diagnosis. * History of vascular insufficiency. * History of neurologic insufficiency. * History of coagulopathy, including previous deep vein thrombosis within six months of Visit 1; and/or therapy with anticoagulation medication (e.g. warfarin). * Radiation treatment within 120 days of Visit 1. * Presence of malignant disease with or without metastases. * Has a life expectancy of less than or equal to 2 years. * History of sickle cell anemia. * Has a known immunodeficiency disorder to include, but not be limited to: AIDS, HIV, etc. * Has participated in another investigation within 30 days of Visit 1. * Has previously received extracorporeal shockwave therapy (ESWT) with a SANUWAVE device.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Bone stress fracture are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

bone fracture Fractures, Stress

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    4 sites. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Harvard - Spaulding Rehabilitation Hospital

    RECRUITING

    Cambridge, Massachusetts, 02138, United States

  • Hospital of Special Surgery (HSS) in NY

    NOT_YET_RECRUITING

    New York, New York, 10021, United States

  • Stanford University Arrillaga Center for Sports and Recreation

    RECRUITING

    Stanford, California, 94305, United States

  • UCLA Ronald Reagan Medical Center

    RECRUITING

    Los Angeles, California, 91803, United States